Condition: Obesity · Sponsor: Charles University, Czech Republic
Weight loss is a cornerstone of diabetes (T2D) management, yet in clinical practice, its delivery is limited by its perceived burdensome nature and variability in response. Personalization of the interventions to increase their success rate is an unmet clinical need. The proposed project MEPHISTO (Whole body and gut microbiome metabolic flexibility to predict lifestyle intervention outcomes) would aim to identify predictive features related to successful weight loss upon sequential exercise and diet intervention in people living with obesity. To this end, the study aims to conduct a clinical trial where the investigators would implement state-of-the-art physiological phenotyping of metabolic flexibility at the whole-body level and at the level of the gut in persons with obesity before and after exercise and diet + exercise intervention to identify predictive signatures of successful weight loss
This description comes directly from the study's public registry record.
Jan Gojda, PhD · +420267163031 · jan.gojda@lf3.cuni.cz
Jana Potočková · +420267163031 · potocko@fnkv.cz
Always discuss trial participation with your own doctor first.
| University Hospital Kralovske Vinohrady | Prague, Czechia | Recruiting |
| Third Medical Faculty,Charles University | Prague, Czechia | Recruiting |
| Faculty of Sports Science | Prague, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06329349